Latest News
& Press Releases

Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.

TOP STORIES
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.
M&A
Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
FDA
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
UPCOMING EVENTS
As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
Across three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw said following the company’s ObesityWeek update.
To achieve a positive return, drugs launched from 2016 to 2020 must generate nearly $12 billion in sales, up from just $1.4 billion for drugs launched in the early 1990s.
Backed by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
PRESS RELEASES
Approximately US$500,000 in potential purchases over the initial three-year term, based on VIVI Cap minimum volumes; agreement targets Qatar’s high-prevalence diabetes market through hospital and pharmacy channels Highlights Exclusive distribution arrangement in Qatar with an initial 36-month term, intended to support local registration, marketing, sale and distribution of TempraMed products Minimum unit purchase commitment with first purchase order paid in full before shipment, represents approximately $US 500,000 potential sales, subject to regulatory clearance, continued compliance with the Distribution Agreement and fulfillment of applicable purchase commitments Qatar had an estimated 409,300 adults with diabetes in 2024 and 24.6% age-standardized adult diabetes prevalence, according to the International Diabetes Federation (IDF) DayMed brings nearly five years of local market experience and reports commercial relationships with hospitals and major pharmacy chains, supporting a focused patient-access strategy
One simulated audio processing update moved 27% to 32% of people between MCI and Alzheimer’s groups in one dataset; recalibration from the audio removed 95% to 97% of the false trend in speech timing features in simulated year-long trials
• First patient recruited for Phase IIa clinical trial • EUR 2.4 million in non-dilutive funding secured from Bpifrance • Final results of Phase I study expected in Q1 2027
MARKET RESEARCH REPORTS